Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray

Aims:  The molecular signature of alveolar soft part sarcoma (ASPS) is a specific der(17)t(X;17)(p11.2;q25) translocation, resulting in a chimeric transcription factor (ASPSCR1–TFE3). When this disease is no longer amenable to surgical curative intervention, uniformly efficacious therapies are lacking. The aim of this study was to evaluate the expression of potential molecular therapeutic targets in a cohort of ASPS tumour samples.

[1]  Joon-Oh Park,et al.  Expression of MET in alveolar soft part sarcoma , 2010, Medical oncology.

[2]  R. Shoemaker,et al.  Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy , 2009, Journal of pediatric hematology/oncology.

[3]  A. R. A. Al Manasra,et al.  Spontaneous regression in alveolar soft part sarcoma: case report and literature review , 2009, World journal of surgical oncology.

[4]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[5]  R. Shoemaker,et al.  BMC Cancer BioMed Central Research article Gene expression profiling of alveolar soft-part sarcoma (ASPS) , 2009 .

[6]  David J. Waxman,et al.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment , 2008, Molecular Cancer Therapeutics.

[7]  A. Lazar,et al.  New Perspectives for Staging and Prognosis in Soft Tissue Sarcoma , 2008, Annals of Surgical Oncology.

[8]  A. Lazar,et al.  Sarcoma epidemiology and etiology: potential environmental and genetic factors. , 2008, The Surgical clinics of North America.

[9]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[10]  L. Trusolino,et al.  The Met tyrosine kinase receptor in development and cancer , 2008, Cancer and Metastasis Reviews.

[11]  A. Lazar,et al.  Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma , 2007, Clinical Cancer Research.

[12]  B. Roufogalis,et al.  Molecular and cellular regulators of cancer angiogenesis. , 2007, Current cancer drug targets.

[13]  Dihua Yu,et al.  High prevalence of p53 exon 4 mutations in soft tissue sarcoma , 2007, Cancer.

[14]  M. Ladanyi,et al.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.

[15]  B. Czerniak,et al.  Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. , 2009, Archives of pathology & laboratory medicine.

[16]  A. Folpe,et al.  Alveolar soft-part sarcoma: a review and update , 2006, Journal of Clinical Pathology.

[17]  T. Ueda,et al.  Alveolar Soft Part Sarcoma in Japan: Multi-Institutional Study of 57 Patients from the Japanese Musculoskeletal Oncology Group , 2003, Oncology.

[18]  K. Hunt,et al.  Alveolar soft part sarcoma , 2001, Cancer.

[19]  Alfons Meindl,et al.  The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 , 2001, Oncogene.

[20]  H. Taubert,et al.  Soft Tissue Sarcomas and p53 Mutations , 1998, Molecular medicine.

[21]  M. Brennan,et al.  Alveolar soft‐part sarcoma. A clinico‐pathologic study of half a century , 1989, Cancer.

[22]  J. Brooks,et al.  Alveolar soft part sarcoma. A clinicopathologic and immunohistochemical study , 1987, Cancer.

[23]  F. W. Foote,et al.  Alveolar soft‐part sarcomas. Structurally characteristic tumors of uncertain histogenesis , 1952, Cancer.